BioSpace News Archive

Frank Gleeson, Chief Executive Officer, Satellos Bioscine shares his Company’s story in an interview with TMX Group.

Adverum Biotechnologies, Inc. announced that R. Andrew “Andy” Ramelmeier, Ph.D., has joined Adverum as the company’s chief technology officer.

Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic pathways, today reported financial results for the second quarter ended June 30, 2023, and provided recent corporate updates.

Agiliti Inc. announced that its board of directors approved a share repurchase program that grants the Company authority to repurchase up to $50 million of shares of the Company’s common stock, over a 12-month period.

Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery and breakthrough diagnostics through ultrasensitive biomarker detection, today announced that it appointed William (Bill) P. Donnelly to its Board of Directors.

Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved ABRYSVO™ (Respiratory Syncytial Virus Vaccine), the company’s bivalent RSV prefusion F (RSVpreF) vaccine, for the prevention of LRTD and severe LRTD caused by RSV in infants from birth up to six months of age by active immunization of pregnant individuals at 32 through 36 weeks gestational age.

Adial Pharmaceuticals, Inc. today provided a business update and reported its financial results for the second quarter of 2023.

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has placed a partial clinical hold on the initiation of new patients in U.S. studies evaluating magrolimab to treat acute myeloid leukemia (AML).

IRLAB Therapeutics, a company discovering and developing novel treatments for Parkinson’s disease, announced the transfer of rights for the now Phase III-ready mesdopetam project to IRLAB.

IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA), a company discovering and developing novel treatments for Parkinson’s disease, today announced further information on the results from mesdopetam’s clinical Phase IIb study in Parkinson’s disease levodopa-induced dyskinesias (PD-LIDs) and Phase III preparatory Phase I studies performed by Ipsen.